Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million
pharmafile | December 20, 2018 | News story | Business Services, Medical Communications, Sales and Marketing |Â Â CAR T, CAR-T, Cancer, Germany, Intrexon, Merck KGaA, darmstadt, oncologyÂ
German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a deal worth $175 million.
Intrexon will hand over $150 million in stock and a $25 million convertible note. The company will in turn receive a $25 million cash investment. Thus Merck will maintain an investment in the next generation of CAR-T therapies.
The new deal comes three years after Merck forged a $941 million deal with Intrexon in 2015. Merck has characterised the move as an attempt to streamline their R&D processes.
However the firm has failed to make a lasting impression when it comes to CAR-T therapies having been overtaken by Swiss firm Novartis and Gilead subsidiary Kite. Shares in Intrexon were up 8% premarket but down overall.
Louis Goss
Related Content
Highlighting the value of lab research for healthcare innovation
Diagnostic innovation and patient safety have dominated this year’s healthcare-focussed awards to mark European Laboratory …
Charity commits £800,000 to AI research into late breast cancer recurrence
Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence to investigate …
Most advanced breast cancer patients treated in community settings, Phesi study finds
Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings …
